Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/12/2019 07/15/2019 07/16/2019 07/17/2019 07/18/2019 Date
85.7(c) 87.55(c) 87.09(c) 88.12(c) 88.51(c) Last
413 922 487 878 548 444 497 936 620 373 Volume
-0.29% +2.16% -0.53% +1.18% +0.44% Change
More quotes
Financials (USD)
Sales 2019 679 M
EBIT 2019 -7,59 M
Net income 2019 -18,1 M
Finance 2019 418 M
Yield 2019 -
Sales 2020 950 M
EBIT 2020 311 M
Net income 2020 284 M
Finance 2020 638 M
Yield 2020 -
P/E ratio 2019 -455x
P/E ratio 2020 30,1x
EV / Sales2019 11,3x
EV / Sales2020 7,83x
Capitalization 8 080 M
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are... 
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
07/10NEUROCRINE BIOSCIENCES : Announces FDA Acceptance of New Drug Application for Op..
PR
07/08NEUROCRINE BIOSCIENCES : Announces Conference Call and Webcast of Second Quarter..
PR
06/17Voyager Therapeutics Up 9%; Restructures Relationship with Sanofi Genzyme
DJ
06/17Voyager Therapeutics Restructures Gene Therapy Relationship with Sanofi Genzy..
DJ
06/11NEUROCRINE BIOSCIENCES : to Present Data on INGREZZA® (valbenazine) and Opicapon..
PR
06/04NEUROCRINE BIOSCIENCES : to Present at Goldman Sachs 40th Annual Global Healthca..
PR
05/30NEUROCRINE BIOSCIENCES : to Present at Jefferies 2019 Global Healthcare Conferen..
PR
05/23NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submissi..
AQ
05/21NEUROCRINE BIOSCIENCES : Presents New Data from RE-KINECT, the Largest Real-Worl..
AQ
05/16NEUROCRINE BIOSCIENCES : Myovants relugolix clears first uterine fibroids PhIII ..
AQ
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, IN
More recommendations
Sector news : Bio Therapeutic Drugs
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Bio Therapeutic Drugs
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 105,41  $
Last Close Price 88,51  $
Spread / Highest target 43,5%
Spread / Average Target 19,1%
Spread / Lowest Target -1,71%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.23.95%8 080
GILEAD SCIENCES7.45%85 092
VERTEX PHARMACEUTICALS6.90%45 369
REGENERON PHARMACEUTICALS-18.85%32 687
SAREPTA THERAPEUTICS INC41.12%11 420
GENMAB13.91%11 276